Posted by Michael Wonder on 02 Mar 2023
FDA accepts for priority review ADX-2191 new drug application for the treatment of primary vitreoretinal lymphoma
2 March 2023 - PDUFA date is 21 June 2023.
Aldeyra Therapeutics today announced that the US FDA accepted for priority review the new drug application for ADX-2191 (methotrexate injection), an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma.
